Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 …
M Westby, M Lewis, J Whitcomb, M Youle… - Journal of …, 2006 - Am Soc Microbiol
Antagonists of the human immunodeficiency virus type 1 (HIV-1) coreceptor, CCR5, are
being developed as the first anti-HIV agents acting on a host cell target. We monitored the …
being developed as the first anti-HIV agents acting on a host cell target. We monitored the …
[PDF][PDF] Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 …
M Westby, M Lewis, J Whitcomb, M Youle… - JOURNAL OF …, 2006 - researchgate.net
MATERIALS AND METHODS Clinical trial design. Trials A4001007 and A4001015 were
designed to evaluate the effect of short-term monotherapy with maraviroc on viral load and …
designed to evaluate the effect of short-term monotherapy with maraviroc on viral load and …
Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 …
M Westby, M Lewis, J Whitcomb, M Youle, AL Pozniak… - 2006 - cabidigitallibrary.org
Antagonists of the human immunodeficiency virus type 1 (HIV-1) coreceptor, CCR5, are
being developed as the first anti-HIV agents acting on a host cell target. We monitored the …
being developed as the first anti-HIV agents acting on a host cell target. We monitored the …
Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 …
M Westby, M Lewis, J Whitcomb, M Youle… - Journal of …, 2006 - europepmc.org
Antagonists of the human immunodeficiency virus type 1 (HIV-1) coreceptor, CCR5, are
being developed as the first anti-HIV agents acting on a host cell target. We monitored the …
being developed as the first anti-HIV agents acting on a host cell target. We monitored the …
[引用][C] Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 …
M WESTBY, M LEWIS, J WHITCOMB… - Journal of …, 2006 - pascal-francis.inist.fr
Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a
minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc …
minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc …
[HTML][HTML] Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the …
M Westby, M Lewis, J Whitcomb, M Youle… - Journal of …, 2006 - ncbi.nlm.nih.gov
Antagonists of the human immunodeficiency virus type 1 (HIV-1) coreceptor, CCR5, are
being developed as the first anti-HIV agents acting on a host cell target. We monitored the …
being developed as the first anti-HIV agents acting on a host cell target. We monitored the …
Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 …
M Westby, M Lewis, J Whitcomb, M Youle… - Journal of …, 2006 - pubmed.ncbi.nlm.nih.gov
Antagonists of the human immunodeficiency virus type 1 (HIV-1) coreceptor, CCR5, are
being developed as the first anti-HIV agents acting on a host cell target. We monitored the …
being developed as the first anti-HIV agents acting on a host cell target. We monitored the …
[PDF][PDF] Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 …
M Westby, M Lewis, J Whitcomb, M Youle… - JOURNAL OF …, 2006 - academia.edu
MATERIALS AND METHODS Clinical trial design. Trials A4001007 and A4001015 were
designed to evaluate the effect of short-term monotherapy with maraviroc on viral load and …
designed to evaluate the effect of short-term monotherapy with maraviroc on viral load and …
Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 …
M Westby, M Lewis, J Whitcomb, M Youle… - Journal of …, 2006 - cir.nii.ac.jp
抄録< jats: title> ABSTRACT</jats: title>< jats: p> Antagonists of the human
immunodeficiency virus type 1 (HIV-1) coreceptor, CCR5, are being developed as the first …
immunodeficiency virus type 1 (HIV-1) coreceptor, CCR5, are being developed as the first …
[HTML][HTML] Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the …
M Westby, M Lewis, J Whitcomb, M Youle, AL Pozniak… - natap.org
Antagonists of the human immunodeficiency virus type 1 (HIV-1) coreceptor, CCR5, are
being developed as the first anti-HIV agents acting on a host cell target. We monitored the …
being developed as the first anti-HIV agents acting on a host cell target. We monitored the …